Combining CG0070 Adenovirus Vector with Immune Checkpoint Blockade: Promising Results for BCG Unresponsive Bladder Cancer Patients - Roger Li

Details

Roger Li joins Ashish Kamat to discuss the CG0070 adenovirus vector and its potential use in combination with immune checkpoint blockade for patients with BCG unresponsive bladder cancer. The combination therapy has shown promising preliminary results, with 20 out of 22 patients achieving a complete response at three months and six out of eight patients maintaining a complete response at 12 months...